Halozyme Therapeutics (HALO)
$
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
About
Business overview of Halozyme Therapeutics (HALO)
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with unmet medical needs, with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. The company's operations are based in the United States, with minimal long-lived assets located internationally.
Key Insights
Critical company metrics and information
Share Price
$48.58Market Cap
$6.18 BillionTotal Outstanding Shares
127.23 Million SharesTotal Employees
373Dividend
No dividendIPO Date
March 12, 2004SIC Description
Biological Products, (no Disgnostic Substances)Homepage
https://www.halozyme.com
Historical Stock Splits
Execution Date | Split Amount |
---|---|
No Historical Stock Splits |
Cash Flow Statement
October 1, 2023 to September 30, 2024
Metric | Value |
---|---|
Net Cash Flow From Investing Activities | $-300.49 Million |
Net Cash Flow, Continuing | $-119.91 Million |
Net Cash Flow From Financing Activities | $-222.37 Million |
Net Cash Flow From Operating Activities | $402.95 Million |
Net Cash Flow From Operating Activities, Continuing | $402.95 Million |
Net Cash Flow | $-119.91 Million |
Net Cash Flow From Investing Activities, Continuing | $-300.49 Million |
Net Cash Flow From Financing Activities, Continuing | $-222.37 Million |
Income Statement
October 1, 2023 to September 30, 2024
Metric | Value |
---|---|
Costs And Expenses | $470.35 Million |
Preferred Stock Dividends And Other Adjustments | $0.00 |
Net Income/Loss Available To Common Stockholders, Basic | $392.47 Million |
Diluted Earnings Per Share | $3.02 |
Net Income/Loss | $392.47 Million |
Basic Earnings Per Share | $3.07 |
Gross Profit | $777.70 Million |
Operating Income/Loss | $477.01 Million |
Income/Loss From Continuing Operations Before Tax | $480.09 Million |
Operating Expenses | $300.69 Million |
Diluted Average Shares | $258.19 Million |
Research and Development | $79.94 Million |
Selling, General, and Administrative Expenses | $149.69 Million |
Other Operating Expenses | $71.05 Million |
Basic Average Shares | $252.91 Million |
Benefits Costs and Expenses | $467.26 Million |
Cost Of Revenue | $169.66 Million |
Income Tax Expense/Benefit | $87.63 Million |
Revenues | $947.36 Million |
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
Income/Loss From Continuing Operations After Tax | $392.47 Million |
Net Income/Loss Attributable To Parent | $392.47 Million |
Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
Balance Sheet
October 1, 2023 to September 30, 2024
Metric | Value |
---|---|
Other Current Liabilities | $96.42 Million |
Prepaid Expenses | $31.05 Million |
Long-term Debt | $1.50 Billion |
Other Current Assets | $964.51 Million |
Noncurrent Liabilities | $1.56 Billion |
Equity Attributable To Noncontrolling Interest | $0.00 |
Equity | $452.70 Million |
Inventory | $131.41 Million |
Other Non-current Assets | $531.49 Million |
Other Non-current Liabilities | $52.36 Million |
Intangible Assets | $419.59 Million |
Accounts Payable | $12.40 Million |
Liabilities | $1.67 Billion |
Current Liabilities | $108.81 Million |
Assets | $2.12 Billion |
Noncurrent Assets | $991.05 Million |
Liabilities And Equity | $2.12 Billion |
Fixed Assets | $39.98 Million |
Current Assets | $1.13 Billion |
Equity Attributable To Parent | $452.70 Million |
Historical Dividends
Announcement Date | Payment Date | Record Date | Amount | Frequency |
---|---|---|---|---|
No historical dividends |
Boost your savings and earn 4.35% APY with a Marcus by Goldman Sachs savings account, a rate that's 8x the national averagewhen signing up with Financhle. No fees, no minimum deposits, backed by the financial expertise of Goldman Sachs. Terms apply.
ⓒ 2024 Financhle. All Rights Reserved.